CDNA

CareDx Inc (CDNA) | Rumor.io

CareDx

CDNA

Attention (50-day avg)0%

Attention rank (50-day avg)#784

Bullish sentiment (50-day avg)83%

Price to earnings ratio31

Market capitalization3.3B

Earnings per share2.08

Dividend yield (TTM)—

Revenue (annual)379.8M

Net income (annual)-21.4M

Social

What share of all stock conversation is about CDNA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% +0.01	0.01% +0	0% +0	0% +0

Sep 24

CareDx, Inc ($CDNA) has a favorable resolution to the LCD issue regarding transplant testing, driving growth in its core business, and expansion into oncology testing through the acquisition of Naveris.
Analysts at BTIG raised their price target for CareDx, Inc ($CDNA) from $60.00 to $74.00 and maintained a Buy rating.
CareDx, Inc ($CDNA) stock is experiencing a significant price increase, with a 15.0% gain today and a 30% gain potential if held, according to a market participant.

Generated by AI

Sentiment

Of the messages about CDNA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	95.41% -3.1	97.4% +31.61	87.14% -1.69
Bearish	0%	4.59% +3.1	2.6% -31.61	12.86% +1.69

Bullish· Apr 16

$CDNA is up 27% today due to a clean setup with smart money zone support and a monthly bull cycle.
The company's sale of $170 million will increase its cash reserves to almost $370 million, leaving it with less than a billion in total capitalization.
The acquisition of Eurobio Scientific provides a major catalyst for $CDNA's momentum surge, with a breakout target of $28.28.

Bearish· Jul 17

$CDNA has dropped -40% with no clear news driving the decline, suggesting a possible scam or manipulation.
The company's $400 million market cap drop is disproportionate to a $20 million settlement with former investors, indicating a potential overreaction.
The stock's sharp decline has led to a significant increase in volume, with some investors expecting a bounce once the panic subsides.

Generated by AI

Topics

Of the messages about CDNA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	100%	93.24%	90.38%	50.06%
Announcements	0%	5.41%	6.73%	42.33%
Analysts	0%	1.35%	2.88%	3.14%
Earnings	0%	0%	0%	4.48%
Controversies	0%	0%	0%	0%
Macro	0%	0%	0%	0%

Announcements· Mar 6

CareDx's stock price fell ~32% and ~16% after MolDX published a revised billing and coding article affecting solid organ transplant rejection testing for Medicare beneficiaries.
CareDx will participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference, with management presenting on March 6th, 2023.
CareDx has updated its participation in the Raymond James & Associates’ 44th Annual Institutional Investors Conference, citing scheduling conflicts and announcing a future corporate update.

Controversies· May 26

CareDx, Inc. (CDNA) is facing a class action lawsuit alleging securities fraud, with investors encouraged to secure counsel before the July 22, 2022 deadline.
Multiple law firms, including Berger Montague and Hagens Berman, are investigating securities fraud allegations against CareDx, Inc. and encouraging investors with significant losses to contact their attorneys.
Investors who purchased CDNA securities between February 24, 2021, and May 5, 2022, may be eligible to participate in a class action lawsuit, with lead plaintiff deadlines and contact information provided.

Generated by AI

Community

Of the messages about CDNA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	83.53%	46.77%	66.22%	55.1%
Newcomers	16.47%	53.23%	33.78%	44.9%

Regulars· May 10

CareDx (CDNA) reported Q1 2024 earnings, beating EPS and revenue estimates, with EPS coming in at -$0.03 and revenue at $63.63M.
CDNA stock surged 27% following the strong earnings, and the company's revenue represents a surprise of +13.24% over the consensus estimate.
The stock has experienced significant growth in volume, with a 162% increase, and some participants are taking profit on CDNA, citing a rollercoaster ride and a desire to exit with a decent gain.

Newcomers· Jul 26

Newcomers to discussing CDNA are focused on avoiding impulsive trading decisions based on recent price movements.
The importance of building a watchlist with a clear trading strategy, rather than following tickers that have recently increased in value.
Sunday watchlists should be used for reflection and planning, rather than as a way to chase recent gains.

Generated by AI

News

CareDx: I Was Wrong, But The Rally Has Outrun The Fundamentals (Rating Upgrade)

CareDx has staged a dramatic turnaround, resolving Medicare risk, returning to profitability, and initiating share buybacks. Read more on CDNA stock here.

4d agoSeeking Alpha

CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar?

CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

5d agoYahoo Finance

CareDx +14% on Fresh $74 Analyst Price Target

CareDx (CDNA) is up about 14% today after BTIG raised its price target from $60 to $74 and maintained its Buy rating. That’s a big move for a target bump – and there may be even more upside to be had… The detailsBTIG hosted CareDx’s CEO, CFO, and head of investor relations for investor meetings in Boston earlier this week, and came away more bullish: Target raised 23%, from $60 to $74Management sounded confident after the positive resolution of the transplant local coverage determination (this i

5d agoYahoo Finance

BTIG raises CareDx stock price target to $74 on transplant outlook

6d agoInvesting.com

Zacks.com featured highlights include CareDx, Ciena, Celestica, Materion and MACOM Technology Solutions

6d agoYahoo Finance

Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently - CareDx (NASDAQ:CDNA), BillionToOne (NA

CMS aligns 2027 clinical lab fees with private payors to save $1 billion, yielding positive updates for CareDx and BillionToOne tests.

6d agoBenzinga

Also Discussed

Investors talking about CDNA also mention

#	Name	Attention
1	Natera, Inc.NTRA	0%-0.01
2	Veracyte, Inc.VCYT	0%new
3	10x Genomics Inc. Class A Common StockTXG	0%-0.02
4	Castle Biosciences Inc.CSTL	0%new
5	Guardant Health Inc.GH	0%-0.11
6	Fortrea Holdings Inc.FTRE	0%0
7	Dianthus Therapeutics Inc.DNTH	0%0
8	Vestis CorporationVSTS	0%new
9	Integra LifeSciences Holdings CorporationIART	0%0
10	Bruker CorpBRKR	0%0

CareDx Inc

Healthcare
Diagnostics & Research

CareDx, Inc. is a precision medicine diagnostics company focused on transplant care and related specialty services. CareDx develops and commercializes non-invasive molecular tests, laboratory products, digital tools, and patient support services that help clinicians monitor organ health before and after transplantation. Its portfolio includes testing solutions for kidney, heart, and lung transplant patients, along with HLA typing and other transplant laboratory products used to support donor-recipient matching and post-transplant surveillance. The company also offers workflow software, data analytics, and care-management tools that connect transplant centers, patients, and providers across the care journey. In addition to its core transplant business, CareDx serves specialty oncology and cell therapy markets with precision diagnostics and support solutions. CareDx, Inc. is headquartered in Brisbane, California.

Website

Location

8000 Marina Boulevard

Brisbane, CA, 94005

United States

Social

What share of all stock conversation is about CDNA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% +0.01	0.01% +0	0% +0	0% +0

Sep 24

CareDx, Inc ($CDNA) has a favorable resolution to the LCD issue regarding transplant testing, driving growth in its core business, and expansion into oncology testing through the acquisition of Naveris.
Analysts at BTIG raised their price target for CareDx, Inc ($CDNA) from $60.00 to $74.00 and maintained a Buy rating.
CareDx, Inc ($CDNA) stock is experiencing a significant price increase, with a 15.0% gain today and a 30% gain potential if held, according to a market participant.

Generated by AI

Sentiment

Of the messages about CDNA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	95.41% -3.1	97.4% +31.61	87.14% -1.69
Bearish	0%	4.59% +3.1	2.6% -31.61	12.86% +1.69

Bullish· Apr 16

$CDNA is up 27% today due to a clean setup with smart money zone support and a monthly bull cycle.
The company's sale of $170 million will increase its cash reserves to almost $370 million, leaving it with less than a billion in total capitalization.
The acquisition of Eurobio Scientific provides a major catalyst for $CDNA's momentum surge, with a breakout target of $28.28.

Bearish· Jul 17

$CDNA has dropped -40% with no clear news driving the decline, suggesting a possible scam or manipulation.
The company's $400 million market cap drop is disproportionate to a $20 million settlement with former investors, indicating a potential overreaction.
The stock's sharp decline has led to a significant increase in volume, with some investors expecting a bounce once the panic subsides.

Generated by AI

Topics

Of the messages about CDNA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	100%	93.24%	90.38%	50.06%
Announcements	0%	5.41%	6.73%	42.33%
Analysts	0%	1.35%	2.88%	3.14%
Earnings	0%	0%	0%	4.48%
Controversies	0%	0%	0%	0%
Macro	0%	0%	0%	0%

Announcements· Mar 6

CareDx's stock price fell ~32% and ~16% after MolDX published a revised billing and coding article affecting solid organ transplant rejection testing for Medicare beneficiaries.
CareDx will participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference, with management presenting on March 6th, 2023.
CareDx has updated its participation in the Raymond James & Associates’ 44th Annual Institutional Investors Conference, citing scheduling conflicts and announcing a future corporate update.

Controversies· May 26

CareDx, Inc. (CDNA) is facing a class action lawsuit alleging securities fraud, with investors encouraged to secure counsel before the July 22, 2022 deadline.
Multiple law firms, including Berger Montague and Hagens Berman, are investigating securities fraud allegations against CareDx, Inc. and encouraging investors with significant losses to contact their attorneys.
Investors who purchased CDNA securities between February 24, 2021, and May 5, 2022, may be eligible to participate in a class action lawsuit, with lead plaintiff deadlines and contact information provided.

Generated by AI

Community

Of the messages about CDNA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	83.53%	46.77%	66.22%	55.1%
Newcomers	16.47%	53.23%	33.78%	44.9%

Regulars· May 10

CareDx (CDNA) reported Q1 2024 earnings, beating EPS and revenue estimates, with EPS coming in at -$0.03 and revenue at $63.63M.
CDNA stock surged 27% following the strong earnings, and the company's revenue represents a surprise of +13.24% over the consensus estimate.
The stock has experienced significant growth in volume, with a 162% increase, and some participants are taking profit on CDNA, citing a rollercoaster ride and a desire to exit with a decent gain.

Newcomers· Jul 26

Newcomers to discussing CDNA are focused on avoiding impulsive trading decisions based on recent price movements.
The importance of building a watchlist with a clear trading strategy, rather than following tickers that have recently increased in value.
Sunday watchlists should be used for reflection and planning, rather than as a way to chase recent gains.

Generated by AI

CareDx

Social

Sep 24

Bullish· Apr 16

Bearish· Jul 17

Announcements· Mar 6

Controversies· May 26

Regulars· May 10

Newcomers· Jul 26

CareDx: I Was Wrong, But The Rally Has Outrun The Fundamentals (Rating Upgrade)

CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar?

CareDx +14% on Fresh $74 Analyst Price Target

BTIG raises CareDx stock price target to $74 on transplant outlook

Zacks.com featured highlights include CareDx, Ciena, Celestica, Materion and MACOM Technology Solutions

Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently - CareDx (NASDAQ:CDNA), BillionToOne (NA

Also Discussed

CareDx Inc

Company Information

Location

CareDx: I Was Wrong, But The Rally Has Outrun The Fundamentals (Rating Upgrade)

CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar?

CareDx +14% on Fresh $74 Analyst Price Target

BTIG raises CareDx stock price target to $74 on transplant outlook

Zacks.com featured highlights include CareDx, Ciena, Celestica, Materion and MACOM Technology Solutions

Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently - CareDx (NASDAQ:CDNA), BillionToOne (NA

Also Discussed

Social

Sep 24

Bullish· Apr 16

Bearish· Jul 17

Announcements· Mar 6

Controversies· May 26

Regulars· May 10

Newcomers· Jul 26